BR112022016746A2 - Sais e formas cristalinas de um agonista de taar1 - Google Patents
Sais e formas cristalinas de um agonista de taar1Info
- Publication number
- BR112022016746A2 BR112022016746A2 BR112022016746A BR112022016746A BR112022016746A2 BR 112022016746 A2 BR112022016746 A2 BR 112022016746A2 BR 112022016746 A BR112022016746 A BR 112022016746A BR 112022016746 A BR112022016746 A BR 112022016746A BR 112022016746 A2 BR112022016746 A2 BR 112022016746A2
- Authority
- BR
- Brazil
- Prior art keywords
- taar1
- crystalline forms
- salts
- taar1 agonist
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20164069 | 2020-03-19 | ||
| PCT/EP2021/056749 WO2021185878A1 (en) | 2020-03-19 | 2021-03-17 | Salts and crystalline forms of a taar1 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022016746A2 true BR112022016746A2 (pt) | 2022-10-11 |
Family
ID=69846246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022016746A BR112022016746A2 (pt) | 2020-03-19 | 2021-03-17 | Sais e formas cristalinas de um agonista de taar1 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12692256B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121428B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023517729A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220155575A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115279752A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021238632A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022016746A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3166331A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3044409T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294301A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010794A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI874616B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021185878A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119654138A (zh) * | 2022-08-12 | 2025-03-18 | 豪夫迈·罗氏有限公司 | 包含5-乙基-4-甲基-n-[4-[(2s)吗啉-2-基]苯基]-1h-吡唑-3-甲酰胺的药物组合物 |
| TW202444712A (zh) * | 2023-04-28 | 2024-11-16 | 大陸商江蘇豪森藥業集團有限公司 | 一種嗎啉雜環類化合物的鹽及其製備方法和應用 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| RS60825B1 (sr) * | 2016-03-17 | 2020-10-30 | Hoffmann La Roche | Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a |
-
2021
- 2021-03-17 IL IL294301A patent/IL294301A/en unknown
- 2021-03-17 CA CA3166331A patent/CA3166331A1/en active Pending
- 2021-03-17 CN CN202180017438.9A patent/CN115279752A/zh active Pending
- 2021-03-17 WO PCT/EP2021/056749 patent/WO2021185878A1/en not_active Ceased
- 2021-03-17 AU AU2021238632A patent/AU2021238632A1/en active Pending
- 2021-03-17 BR BR112022016746A patent/BR112022016746A2/pt unknown
- 2021-03-17 MX MX2022010794A patent/MX2022010794A/es unknown
- 2021-03-17 JP JP2022555821A patent/JP2023517729A/ja active Pending
- 2021-03-17 TW TW110109520A patent/TWI874616B/zh active
- 2021-03-17 EP EP21712158.1A patent/EP4121428B1/en active Active
- 2021-03-17 ES ES21712158T patent/ES3044409T3/es active Active
- 2021-03-17 KR KR1020227031814A patent/KR20220155575A/ko active Pending
-
2022
- 2022-09-16 US US17/946,743 patent/US12692256B2/en active Active
-
2025
- 2025-08-07 JP JP2025132332A patent/JP2025166092A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4121428B1 (en) | 2025-08-13 |
| EP4121428C0 (en) | 2025-08-13 |
| WO2021185878A1 (en) | 2021-09-23 |
| US20230120311A1 (en) | 2023-04-20 |
| MX2022010794A (es) | 2022-09-27 |
| TWI874616B (zh) | 2025-03-01 |
| CN115279752A (zh) | 2022-11-01 |
| KR20220155575A (ko) | 2022-11-23 |
| US12692256B2 (en) | 2026-07-28 |
| CA3166331A1 (en) | 2021-09-23 |
| JP2025166092A (ja) | 2025-11-05 |
| TW202140466A (zh) | 2021-11-01 |
| AU2021238632A1 (en) | 2022-07-14 |
| ES3044409T3 (en) | 2025-11-26 |
| EP4121428A1 (en) | 2023-01-25 |
| JP2023517729A (ja) | 2023-04-26 |
| IL294301A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066420A1 (es) | Composicion farmaceutica suministrable oronasofaringeamente para la prevencion alivio / y o tratamiento de trastornos de miembros inquietos. uso. | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| CU23808B7 (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
| BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
| BR112019003811A2 (pt) | composição farmacêutica, método para aumentar os níveis plasmáticos de antagonista do receptor de nmda em um sujeito que precisa do mesmo, método para tratar uma doença ou transtorno em um sujeito que precisa do mesmo e uso da composição | |
| BRPI0415953B8 (pt) | formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada | |
| BR112021023770A2 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| BR112013006030A2 (pt) | composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica | |
| BRPI0708071A8 (pt) | Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos | |
| AR117655A1 (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| BR112021009078A8 (pt) | Antagonistas substituídos de receptor de adenosina de aminotriazolopirimidina e aminotriazolopirazina, composições farmacêuticas e seus usos | |
| MX2023006751A (es) | Nuevo derivado de camptotecina, composicion que comprende el mismo y su uso. | |
| BRPI0618479A2 (pt) | pirrolpiridinas composição farmacêutica que as contém | |
| BRPI0920605A8 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste. | |
| BR112023007912A2 (pt) | Formas cristalinas de um composto inibidor de kras g12c | |
| MX2022010794A (es) | Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1). | |
| BR112021024380A2 (pt) | Formulações de liberação modificadas e usos das mesmas | |
| PE20221455A1 (es) | Composicion farmaceutica que comprende selexipag | |
| CO2024015586A2 (es) | Compuesto de sal de amonio cuaternario cíclico, método de preparación para el mismo y uso del mismo | |
| CL2020000601A1 (es) | Composición farmacéutica. | |
| PE20070521A1 (es) | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a | |
| BR112023021146A2 (pt) | Compostos cristalinos de antagonistas do receptor muscarínico de acetilcolina m1 | |
| BRPI0923373B8 (pt) | composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação | |
| BR112018073743A2 (pt) | composto, processo, método para tratamento de infecção bacteriana em um sujeito, uso de um composto, e composições farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |